by nms-sync | Nov 4, 2022 | News
A week from the presentation of Nerviano Medical Sciences S.r.l. (a member of NMS Group) on NMS-01940153E (NMS-153) at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, we’re thrilled to share the official press release from ENA 2022 of...
by nms-sync | Oct 31, 2022 | News
NERVIANO, 31 October 2022 – Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that Salvatore Marengoni Galdy, M.D., has joined the...
by nms-sync | Oct 28, 2022 | News
Nerviano Medical Sciences S.r.l. Shared Data on NMS-01940153E selected for Oral Presentation at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
NERVIANO, 28 October 2022 – Nerviano Medical Sciences Srl (Company), a member of NMS...
by nms-sync | Oct 26, 2022 | News
NERVIANO, 25 October 2022 – Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that preclinical data from the Company’s asset NMS-03602173 will...
by nms-sync | Oct 17, 2022 | News
Nerviano Medical Sciences S.r.l. Announces Data on NMS-01940153E selected for Oral Presentation at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
NERVIANO, 18 October 2022 – Nerviano Medical Sciences Srl (Company), a member of...
by NMSGroup | Sep 21, 2022 | News
NERVIANO, 21 September 2022 Nerviano Medical Sciences S.r.l. (NMS), a member of the NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, announced today the signing of a collaboration agreement ...
Welcome and Check out our new motion picture!
Recent Comments